Table 2.
Most common (≥20%) treatment‐emergent adverse events by dose cohort
| Preferred Term |
60 mg/7‐day (DL1) N = 6 n (%) |
60 mg/14‐day (DL2) N = 7a n (%) |
40 mg/14‐day (DL‐1) N = 6 n (%) |
TOTAL N = 19 n (%) |
|---|---|---|---|---|
| Nausea | 5 (83) | 6 (86) | 4 (67) | 15 (79) |
| Diarrhea | 3 (50) | 4 (57) | 5 (83) | 12 (63) |
| Constipation | 3 (50) | 5 (71) | 3 (50) | 11 (58) |
| Hypokalemia | 4 (67) | 4 (57) | 2 (33) | 10 (53) |
| Hypomagnesemia | 3 (50) | 5 (71) | 2 (33) | 10 (53) |
| Neutropenia | 5 (83) | 3 (43) | 2 (33) | 10 (53) |
| Febrile neutropenia | 3 (50) | 3 (43) | 3 (50) | 9 (47) |
| Vomiting | 4 (67) | 3 (43) | 2 (33) | 9 (47) |
| Fatigue | 2 (33) | 3 (43) | 2 (33) | 7 (37) |
| Headache | 2 (33) | 3 (43) | 2 (33) | 7 (37) |
| Hypophosphatemia | 4 (67) | 3 (43) | 0 | 7 (37) |
| Hypotension | 2 (33) | 2 (29) | 3 (50) | 7 (37) |
| Pyrexia | 3 (50) | 2 (29) | 2 (33) | 7 (37) |
| Rash | 2 (33) | 2 (29) | 3 (50) | 7 (37) |
| Anemia | 3 (50) | 2 (29) | 1 (17) | 6 (32) |
| Anxiety | 2 (33) | 3 (43) | 1 (17) | 6 (32) |
| Hemorrhoids | 2 (33) | 1 (14) | 3 (50) | 6 (32) |
| Hypocalcemia | 3 (50) | 1 (14) | 2 (33) | 6 (32) |
| Thrombocytopenia | 4 (67) | 1 (14) | 1 (17) | 6 (32) |
| Abdominal pain | 2 (33) | 1 (14) | 2 (33) | 5 (26) |
| Drug eruption | 1 (17) | 4 (57) | 0 | 5 (26) |
| Dyspepsia | 2 (33) | 2 (29) | 1 (17) | 5 (26) |
| Dyspnea | 2 (33) | 3 (43) | 0 | 5 (26) |
| Hypertension | 4 (67) | 1 (14) | 0 | 5 (26) |
| Hypoalbuminemia | 1 (17) | 2 (29) | 1 (17) | 4 (21) |
| Mucosal inflammation | 2 (33) | 2 (29) | 0 | 4 (21) |
| Edema, peripheral | 2 (33) | 0 | 2 (33) | 4 (21) |
DL, dose level.
a
One patient enrolled in the DL2 cohort discontinued on day 3 before receiving quizartinib.